Search results
Showing 2686 to 2700 of 8908 results
Type 2 diabetes: insulin degludec/liraglutide (Xultophy) (ESNM60)
Summary of the evidence on insulin degludec/liraglutide (Xultophy) for treating type 2 diabetes to inform local NHS planning and decision-making
Orthostatic hypotension due to autonomic dysfunction: midodrine (ESNM61)
Summary of the evidence on midodrine for orthostatic hypotension due to autonomic dysfunction to inform local NHS planning and decision-making
Summary of the evidence on cangrelor for coronary revascularisation to inform local NHS planning and decision-making
Minimal change disease and focal segmental glomerulosclerosis in adults: rituximab (ES1)
Summary of the evidence on rituximab for minimal change disease and focal segmental glomerulosclerosis to inform local NHS planning and decision-making
Prevention of chemotherapy induced nausea and vomiting in adults: netupitant/palonosetron (ESNM69)
Summary of the evidence on netupitant/palonosetron to prevent chemotherapy induced nausea and vomiting to inform local NHS planning and decision-making
Reversal of the anticoagulant effect of dabigatran: idarucizumab (ESNM73)
Summary of the evidence on idarucizumab for reversing the anticoagulant effect of dabigtatran to inform local NHS planning and decision-making
Complicated urinary tract infections: ceftolozane/tazobactam (ESNM74)
Summary of the evidence on ceftolozane/tazobactam for treating complicated urinary tract infections to inform local NHS planning and decision-making
Complicated intra-abdominal infections: ceftolozane/tazobactam (ESNM75)
Summary of the evidence on ceftolozane/tazobactam for treating complicated intra-abdominal infections to inform local NHS planning and decision-making
Immune (idiopathic) thrombocytopenic purpura: rituximab (ESUOM35)
Summary of the evidence on rituximab for immune (idiopathic) thrombocytopenic purpura in adults to inform local NHS planning and decision-making
Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making
Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate (ESUOM4)
Summary of the evidence on oral magnesium glycerophosphate for preventing recurrent hypomagnesaemia to inform local NHS planning and decision-making
Summary of the evidence on sildenafil for managing digital ulcers to inform local NHS planning and decision-making
Prevention of recurrence of C3 glomerulopathy post-transplant: eculizumab (ESUOM44)
Summary of the evidence on eculizumab to prevent the recurrence of C3 glomerulopathy post-transplant to inform local NHS planning and decision-making
Summary of the evidence on ramipril for relieving the symptoms of peripheral arterial disease (PAD) to inform local NHS planning and decision-making
Summary of the evidence on oral erythromycin for gastroparesis (delayed stomach emptying) in adults to inform local NHS planning and decision-making